Why the study?
Do calcium channel blockers prevent the progression of diabetic kidney disease in patients with diabetes and animal models?
Do calcium channel blockers prevent the progression of diabetic kidney disease in patients with diabetes and animal models?
This review highlights the controversial renoprotective effects of CCBs in diabetes, suggesting potential differences between dihydropyridine and non-dihydropyridine classes, and raises safety concerns regarding cardiovascular mortality with certain CCBs.
No takes yet. Share an insight, caveat, or question.
Mixed experimental CCB data in diabetic models warrant clinical caution; leaves open class-specific renoprotection for targeted trials.
Nielsen et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: